RxDoctor Payments Data

Subbarao Gorti, MD

Family Medicine · Bensalem, PANPI 1356399075

Payments from drug & device makers

$4,088in general payments, 2019–2025

Across 222 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$648
  • Novo Nordisk$633
  • Lilly USA, LLC$284
  • Exact Sciences$249
  • Amarin Pharma, Inc.$190
  • plus $892 from 17 others

What the payments were for

  • Food & beverage$4,02398%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,088 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$34,735
Medicare patients
125
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$49,086
EliquisApixaban34$46,642
FarxigaDapagliflozin Propanediol19$24,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$23,721
OzempicSemaglutide19$23,311
XareltoRivaroxaban12$18,925
LinzessLinaclotide15$11,291
TrulicityDulaglutide11$10,692
Varenicline Tartrate19$5,770
Fluticasone-SalmeterolFluticasone Propion/Salmeterol42$4,939
Atorvastatin Calcium360$4,398
Testosterone11$3,934
Albuterol Sulfate HfaAlbuterol Sulfate151$3,757
Advair HfaFluticasone Propion/Salmeterol11$3,128
Levothyroxine Sodium183$2,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$73$49,08646 claims
PfizerEliquis, Paxlovid$124$48,01051 claims
AstraZenecaFarxiga$648$24,01219 claims
GSKTrelegy Ellipta$56$23,72124 claims
Novo NordiskOzempic$633$23,31119 claims
Johnson & JohnsonXarelto$134$18,92512 claims
AbbVieLinzess$1,193$11,29115 claims
Lilly USA, LLCTrulicity$284$10,69211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Bensalem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →